Elon Musk’s Neuralink will likely collect sizeable revenue from its N1 brain implant in out years, according to an analyst at Ark Investment Management.

What Happened: If the N1 module and R1 surgical robot succeed in getting FDA approval for ALS, a neurodegenerative disorder that results in progressive degeneration of nerve cells in the spinal cord and brain, and cervical spinal cord injuries, there will likely be modest adoption by 2025, said Ark analyst Pierce Jamieson.

Neuralink’s N1 implant is cosmetically invisible and is intended to record and transmit brain signals wirelessly to an app that decodes movement intention. The R1 Robot will be used to surgically place the N1 Implant's ultra-fine and flexible threads in a region of the brain that ...

Full story available on Benzinga.com